These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

874 related articles for article (PubMed ID: 34721032)

  • 1. Comparison of Safety and Efficacy Between Clopidogrel and Ticagrelor in Elderly Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis.
    Zhao X; Zhang J; Guo J; Wang J; Pan Y; Zhao X; Sang W; Yang K; Xu F; Xu F; Chen Y
    Front Pharmacol; 2021; 12():743259. PubMed ID: 34721032
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular Outcomes Observed with Ticagrelor versus Clopidogrel in Type 2 Diabetes Mellitus Patients with Acute Coronary Syndrome: A Meta-analysis.
    Jiang Z; Liu L; Bundhun PK
    Diabetes Ther; 2023 Feb; 14(2):387-399. PubMed ID: 36542307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
    Ohman EM; Roe MT; Steg PG; James SK; Povsic TJ; White J; Rockhold F; Plotnikov A; Mundl H; Strony J; Sun X; Husted S; Tendera M; Montalescot G; Bahit MC; Ardissino D; Bueno H; Claeys MJ; Nicolau JC; Cornel JH; Goto S; Kiss RG; Güray Ü; Park DW; Bode C; Welsh RC; Gibson CM
    Lancet; 2017 May; 389(10081):1799-1808. PubMed ID: 28325638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: Systematic review and meta-analysis.
    Fujisaki T; Kuno T; Ando T; Briasoulis A; Takagi H; Bangalore S
    Am Heart J; 2021 Jul; 237():34-44. PubMed ID: 33737060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prasugrel vs Ticagrelor for DAPT in Patients with ACS Undergoing PCI: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Al-Abdouh A; Barbarawi M; Abusnina W; Amr M; Zhao D; Savji N; Hasan RK; Michos ED
    Cardiovasc Revasc Med; 2020 Dec; 21(12):1613-1618. PubMed ID: 32513604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    You SC; Rho Y; Bikdeli B; Kim J; Siapos A; Weaver J; Londhe A; Cho J; Park J; Schuemie M; Suchard MA; Madigan D; Hripcsak G; Gupta A; Reich CG; Ryan PB; Park RW; Krumholz HM
    JAMA; 2020 Oct; 324(16):1640-1650. PubMed ID: 33107944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coronary Heart Disease (CHD) in Elderly Patients: Which Drug to Choose, Ticagrelor and Clopidogrel? A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Akkaif MA; Sha'aban A; Daud NAA; Yunusa I; Ng ML; Sk Abdul Kader MA; Noor DAM; Ibrahim B
    J Cardiovasc Dev Dis; 2021 Sep; 8(10):. PubMed ID: 34677192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-Analysis Comparing P2Y
    Baldetti L; Melillo F; Moroni F; Gallone G; Pagnesi M; Venuti A; Beneduce A; Calvo F; Gramegna M; Godino C; D'Ascenzo F; De Ferrari GM; Capodanno D; Cappelletti AM
    Am J Cardiol; 2020 Jun; 125(12):1815-1822. PubMed ID: 32305225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial.
    Ge Z; Gao XF; Kan J; Kong XQ; Zuo GF; Ye F; Tian NL; Lin S; Liu ZZ; Shao YB; He YQ; Wen SY; Yang Q; Xia Y; Wang ZZ; Xiao PX; Li F; Zeng HS; Yang S; Wang Y; Tao L; Gao DS; Qu H; Qian XS; Han YL; Chen F; Zhang JJ; Chen SL
    Am Heart J; 2021 Jun; 236():49-58. PubMed ID: 33621541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meta-Analysis of the Relative Efficacy and Safety of Oral P2Y12 Inhibitors in Patients With Acute Coronary Syndrome.
    Shah R; Rashid A; Hwang I; Fan TM; Khouzam RN; Reed GL
    Am J Cardiol; 2017 Jun; 119(11):1723-1728. PubMed ID: 28385176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Ticagrelor Compared to Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis.
    Wu H; Xiang X; Li D; Shen S; Li X
    Curr Pharm Des; 2020; 26(46):5988-5997. PubMed ID: 32534561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Potent Oral P2Y
    Ma S; Li Z; Yu P; Song H; Jiang Z; Li Y; Han Y
    Cardiovasc Drugs Ther; 2020 Apr; 34(2):199-208. PubMed ID: 32006144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
    Abergel E; Nikolsky E
    Vasc Health Risk Manag; 2010 Oct; 6():963-77. PubMed ID: 21057581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
    Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
    Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of High Potent P2Y
    Schreuder MM; Badal R; Boersma E; Kavousi M; Roos-Hesselink J; Versmissen J; Visser LE; Roeters van Lennep JE
    J Am Heart Assoc; 2020 Feb; 9(4):e014457. PubMed ID: 32063118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing the effectiveness and safety of dual antiplatelet with ticagrelor or clopidogrel in elderly Asian patients with acute myocardial infraction.
    Yeh JS; Chen WT; Tomlinson B; Tam WC; Chien LN
    Front Cardiovasc Med; 2023; 10():1143509. PubMed ID: 37008324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
    O'Donoghue ML; Murphy SA; Sabatine MS
    Circulation; 2020 Aug; 142(6):538-545. PubMed ID: 32551860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients-A 10-year cohort study.
    Lam ASM; Yan BPY; Lee VWY
    Clin Cardiol; 2021 Aug; 44(8):1072-1079. PubMed ID: 34041774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P2Y12 Inhibitor Monotherapy Versus Conventional Dual Antiplatelet Therapy or Aspirin Monotherapy in Acute Coronary Syndrome: A Pooled Analysis of the SMART-DATE and SMART-CHOICE Trials.
    Song PS; Park YH; Oh JH; Song YB; Choi SH; Gwon HC; Cho DK; Rha SW; Bae JW; Jeong JO; Hahn JY;
    Am J Cardiol; 2021 Jul; 150():47-54. PubMed ID: 34011436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.